Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- CheckyesterdayChange DetectedThe history now shows the addition of Revision: v3.6.3 and the removal of Revision: v3.6.2, signaling a new site release label. This reflects a minor update to the page's release version in the record history without changes to the underlying study information.SummaryDifference0.1%

- Check8 days agoChange DetectedThe record history now includes a new site revision entry (v3.6.2). The previous revision (v3.6.0) has been removed, indicating a backend version update rather than changes to trial data.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe history now shows that the study is no longer recruiting participants, indicating enrollment closure. It also adds a new revision tag (v3.6.0) and removes the previous revision tag (v3.5.5), reflecting an updated version in the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedThe history now lists a new revision v3.5.5 and removes the previous v3.5.4, reflecting a minor page release in the metadata.SummaryDifference0.1%

- Check51 days agoChange DetectedA new revision tag (v3.5.4) has been added to the record history, and the previous revision tag (v3.5.3) has been removed from the history.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision tag updated from v3.5.2 to v3.5.3 in the page history, signaling a new build of the page. This change reflects an internal update to the page version and does not affect study data or visible content.SummaryDifference0.1%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.